ORIGINAL RESEARCH PAPER

BENEFITS OF THYMECTOMY IN MYASTHENIA GRAVIS

Dr Manoj M Joshi  M. S, M. Ch, Dept Of Cardio Vascular Thoracic Surgery ,grant Govt Medical College & Sir JJ Group Of Hospitals, Mumbai.

Dr Hrishikesh Parashi* M. S, M. Ch, Dept Of Cardio Vascular Thoracic Surgery ,grant Govt Medical College & Sir JJ Group Of Hospitals, Mumbai. *Corresponding Author

Dr Vignesh Ravikumar  M. S, M. Ch, Dept Of Cardio Vascular Thoracic Surgery ,grant Govt Medical College & Sir JJ Group Of Hospitals, Mumbai.

ABSTRACT

In recent years, thymectomy has become a widespread procedure in the treatment of myasthenia gravis (MG). Likelihood of remission was highest in preoperative mild disease classification (Osserman classification 1, 2A). In absence of thymoma or hyperplasia, there was no relationship between age and gender in remission with thymectomy. In MG treatment, randomized trials that compare conservative treatment with thymectomy have started, recently. As with non-randomized trials, remission with thymectomy in MG treatment was better than conservative treatment with only medication. There are four major methods for the surgical approach: transcervical, minimally invasive, transsternal, and combined transcervical transsternal thymectomy. Transsternal approach with thymectomy is the accepted standard surgical approach for many years. In recent years, the incidence of thymectomy has been increasing with minimally invasive techniques using thoracoscopic and robotic methods. There are no randomized, controlled studies which are comparing surgical techniques. However, when comparing non-randomized trials, it is seen that minimally invasive thymectomy approaches give similar results to more aggressive approaches.

INTRODUCTION

Myasthenia gravis is an autoimmune disorder that affects the postsynaptic acetylcholine receptors of voluntary muscle and results in weakness and fatigue of the affected muscle group. Medical treatment involves the use of anticholinesterase agents, immunosuppressive drugs, plasmapheresis and gammaglobulin, with reported complete remission rates (CCRIs) of only 15%. A relationship between the thymus and myasthenia gravis was demonstrated in 1901; but it was Blalock et al in 1939 who first demonstrated the beneficial effect of thymectomy. Since then thymectomy has become an increasingly accepted procedure in the treatment of myasthenia gravis, as it can achieve complete clinical remission rates as high as 80% in accordance with most of the reports published in the literature. However controversy still persists regarding appropriate selection of patients, the optimal surgical approach, and the extent of mediastinal dissection required. The purpose of the present study was to assess the results obtained by thymectomy for myasthenia gravis in a series of 57 patients, quantify the degree of clinical improvement following thymectomy by assessing changes in both stage and medication requirement and to identify prognostic factors that may be useful in deciding optimal patient selection.

MATERIAL AND METHODS

The study group comprises of 57 patients with myasthenia gravis who were admitted in Grant Govt Medical College and Sir JJ Hospital, Mumbai and underwent trans-sternal total thymectomy during the period of January 2000 to December 2007. Each patient was evaluated before surgery by the neurologist and diagnosis was based on clinical signs and symptoms, positive response to edrophonium chloride test, and electromyography test. All patients underwent clinical staging based on the modified Osserman classification. Indications for surgical therapy included persistent generalized myasthenia gravis while on medical regimen, persistent ocular myasthenia gravis under appropriate medical treatment and presence of a thymoma as diagnosed by computed tomography. Before surgery each patient underwent routine chest x-ray, and computed tomography of chest. Laboratory studies included radioimmunoassay for the acetylcholine receptor antibody level, immunoglobulin level, serum complement test, thyroid function test and serum studies for antithyroid antibodies.

All 57 patients underwent median sternotomy and trans-sternal thymectomy. All thymic tissue and anterior mediastinal fat were removed from the lower limit of the pericardium inferiorly to the cervical thymic extension superiorly and from one phrenic nerve to the other. Attempts were made to remove all involved tissue in the patients with invasive thymoma. Surgical procedures were performed using general anesthesia. Following surgery, all the patients were managed in an intensive care unit and were maintained on mechanical ventilation. All patients who had received anticholinesterase inhibitor (AchEI) prior to surgery received these agents one hour prior to extubation. Recorded preoperative data included age, sex, Osserman stage, medication requirement, laboratory studies, duration of disease and coexistent medical conditions. Following surgery, the time to extubation, thymic abnormality, complications and length of hospitalization were recorded.

After discharge patients were followed up at varying intervals; the mean follow up was 2.4 years. All patients were interviewed by a neurologist and explicit details of exercise tolerance, employment, Osserman stage, medication requirement, complications and follow-up duration were recorded.

Patients response to thymectomy was graded according to Milichat and Dodge criteria of follow up. A) Complete clinical remission of symptoms and off anticholinesterase inhibitor for more than 50 days.
RESULTS

57 patients underwent thymectomy at Grant Govt Medical College & Sir JJ Hospital, Mumbai. Thirty-two patients (56.1%) were male and twenty-five (43.9%) female aged between 8 and 59 years. The mean age was 33.3 years. Application of Ossermans classification yielded the following as shown in (Table 1) grade I-9 patients; grade IIA-27 patients; grade IIB - 14 patients, grade III-5 patients and grade IV-2 patients.

Time elapsed from diagnosis to operation was 2 years in 42 patients (73.70%) and more than 2 years in 15 patients (26.3%). Before thymectomy 20 patients were on anticholin in estrase agents, 3 on corticosteroids, 5 on anticholinesterase and 18 on anticholinesterase and immunosuppressants and 14 patients were on combined regimen of the drugs and had undergone plasmapheresis. There was 3.5% (2 patients) mortality in hospital, both patients belonged to Ossermans grade IIB and had myasthenic crisis. One patient developed disseminated intrav asular coagulation, Sepsicemia and expired on the 5th post-operative day. The second patient needed tracheostomy and prolonged ventilation, with multiple cycles of plasmapheresis and steroids but the patient expired on the 108th post-operative day. There is no late post-operative death on followup. 3 patients had postoperative complications (1 right sided pneumothorax, 1 Left Lower Lobe pneumonia, 1 surgical wound infection). Late complication on follow up were present in 2 patients, (1 patient had recurrence of thymoma 3 months after surgery, 1 discharging sinus over sternal region). 10 patients had severe myasthenic crisis postoperatively. They were intubated, ventilated, treated with multiple cycles of plasmapheresis, prednisolone and anticholinesterase agents. Of these 5 are in remission, 3 patients had improvement & 2 patients expired as already discussed in mortality. Post-operative pathologic study of the thymus revealed hyperplasia of thymus in 21 patients (36.8%), thymoma in 12 patients (21.1%) including a case of thymic carcinoma, atrophy in 5 patients (8.8%), normal thymus in 19 patients (33.3%).

In the present study 13 patients (20.6%) had associated comorbid disease along with myasthenia gravis. 5 patients had coexisting autoimmune disease (3 Patients had thyrotoxicosis, 1 patient had systemic lupus erythematosus and choloquine induced keratopathy, 1 patient had antiphospholipid antibody syndrome), 5 patients had steroid induced Cushings disease, 1 patient had steroid induced diabetes mellitus, 1 patient had hypertension, and 1 patient had pulmonary tuberculosis. The mean hospital stay in the present study was 15 days with 3 patients having prolonged hospital stay due to complications. Follow up ranged from 6 months to 9 years. Mean follow up is 2.4 years. According to Milichat and Dodge criteria, 31 patients (54.4%) had complete clinical remission, 9 (15.8%) had clinical improvement, 12 (21.1%) had no improvement, 3 patients (6.3%) worsened after thymectomy & 2 (3.5%) patients expired. With respect to correlation of the prognostic factor to complete clinical remission, it is noteworthy that 17 female patients achieved complete clinical remission as compared to 14 male patients. Thus, female sex had better outcome after thymectomy (p<0.04).

In the present study, age, histopathological characteristic of the excised thymus and duration of disease did not correlate with the outcome after thymectomy for myasthenia gravis. However, large number of studies have shown that myasthenic patients with younger age were significantly more likely to benefit from thymectomy than older age, hyperplastic excised thymus and shorter duration from onset of disease to surgery are associated with better clinical response after thymectomy for myasthenia gravis. The surgical outcome of patients in different Osserman stages were analysed. Most of the patients who achieved complete clinical remission belonged to Osserman stage I, IIA & III (P=0.021) (Table 2). The study further demonstrated decreasing response to surgery with incre asing Osserman stage (P=0.007).

Post-operative medication requirement was recorded at the time of last followup. (Table 3). In general, patients continued receiving the minimal dose necessary to control symptoms effectively and were weaned off medications as tolerated. A significant correlation was found between outcome and post-operative medication requirement (p=0.001) indicating, medication requirement decrease after thymectomy.

DISCUSSION

Thymectomy for myasthenia gravis had its origin in 1939 when Alfred Blalock & associates successfully resected the thymus containing a thymic cyst from a 26-year-old woman with myasthenia gravis. Myasthenia gravis is an autoimmune disease impairing neuromuscular transmission because of binding of antiobio to acetylcholine receptors. The condition may affect any age group, with peak incidence in women in their thirties & forties and men aged between sixties and seventies. Initially involved site is most often the eye with about 80% experiencing generalized muscular weakness. Medical treatment for myasthenia gravis consist of anticholinesterase agents, steroids, immunosuppressive & plasmapheresis to reduce serum antibody concentration. A complete clinical remission rate as low as 15% after medical treatment has been reported.1,3,4 Surgical treatment has become an increasingly accepted procedure resulting in complete clinical remission rate as high as 42% and clinical improvement in up to 94% cases.7,10,11 Trans sternal approach for thymectomy is the standard procedure and we followed to extirpate all the thymic tissue including the adipose tissue at

---

<table>
<thead>
<tr>
<th>Class</th>
<th>No of patients</th>
<th>Remission</th>
<th>Improvement</th>
<th>No Improvement</th>
<th>Worse</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>9</td>
<td>15.78</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIA</td>
<td>27</td>
<td>47.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIB</td>
<td>14</td>
<td>24.56</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>5</td>
<td>8.77</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>2</td>
<td>3.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Table 2 Osserman

<table>
<thead>
<tr>
<th>No of Drugs</th>
<th>Before Surgery</th>
<th>After Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Pyridostigmine</td>
<td>20</td>
<td>8</td>
</tr>
<tr>
<td>5 Pyridostigmine + Azathioprin 15</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>9 Combination + pheresis</td>
<td>14</td>
<td>10</td>
</tr>
<tr>
<td>4 Steroids</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>5 Pyridostigmine + steroids</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>6 None</td>
<td>-</td>
<td>31</td>
</tr>
</tbody>
</table>
Myasthenia gravis with ocular involvement remains a controversial indication for thymectomy. Untreated, 2/3rd of them will develop generalized myasthenia gravis. Papatestas and colleagues showed greater improvement in patient with mild generalized symptoms. Other investigators have been unable to show a significant difference in the results with preoperative stage.

Medication requirement in patients of myasthenia gravis decreases significantly after thymectomy. Our study fully agrees with these finding, and there is strong relation between thymectomy and reduced postoperative medication requirement. In summary, on the basis of our results we agree with these finding, and there is strong relation between thymectomy and reduced postoperative medication requirement. In the present study pathology did not correlate with the outcome. Our conclusion, that the patient with thymoma did not show a poor response to thymectomy than those with non–neoplastic thymus gland is in agreement with the findings of Olanow and colleagues.

Are the main prognostic factors determining the outcome. Medication requirement decreases post-operatively. We also advocate thymectomy for ocular myasthenia gravis.

REFERENCES